These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12470797)

  • 1. Emerging Alzheimer's disease therapies: inhibition of beta-secretase.
    Citron M
    Neurobiol Aging; 2002; 23(6):1017-22. PubMed ID: 12470797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-secretase as a target for the treatment of Alzheimer's disease.
    Citron M
    J Neurosci Res; 2002 Nov; 70(3):373-9. PubMed ID: 12391600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human beta-secretase and Alzheimer's disease.
    Citron M
    Expert Opin Ther Targets; 2001 Jun; 5(3):341-348. PubMed ID: 12540269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
    Read J; Suphioglu C
    Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BACE, a promising approach to Alzheimer's disease therapy.
    Roggo S
    Curr Top Med Chem; 2002 Apr; 2(4):359-70. PubMed ID: 11966460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
    Evin G; Hince C
    Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
    Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
    J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
    Citron M
    Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
    Das B; Yan R
    CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
    Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
    Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
    Hussain I
    IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
    Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
    PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.